Bispecific Binding Molecules Targeting ROR1 and CD3
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific binding molecules for cancer treatment lack a reliable method to optimize parameters such as antigen-binding affinity and valency, making it challenging to design molecules that effectively target ROR1 and CD3 for therapeutic use.
Innovation Solution
Development of novel bispecific binding molecules with specific antigen-binding domains that target ROR1 and CD3, comprising specific amino acid sequences and configurations to enhance binding affinity and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific binding molecules are designed to target both ROR1 and CD3, then T cell activation and cytotoxicity against cancer cells is enhanced, but the complexity of designing molecules with optimized binding affinity and valency increases
Solution Approach 1:
The bispecific binding molecule is divided into distinct functional domains: an anti-ROR1 binding domain (comprising heavy chain variable domain VH and light chain variable domain VL with specific amino acid sequences) and an anti-CD3 binding domain. This segmentation allows independent optimization of each antigen-binding specificity while maintaining overall molecular function, thereby enhancing therapeutic efficacy without overwhelming design complexity.
Solution Approach 2:
The patent optimizes specific parameters including the amino acid sequences of the variable domains, the valency of antigen binding, and the spatial configuration of paratopes. By systematically varying these parameters across different molecular constructs, the invention identifies optimal combinations that maximize T cell activation and cytotoxicity while managing design complexity through structured parameter exploration.
2Reliability
If multiple parameters such as PK, antigen epitopes, and paratope configuration are optimized, then in vivo potency is improved, but the time and resources required for systematic evaluation increase
Solution Approach 1:
The patent performs preliminary optimization of key parameters including selection of specific antigen epitopes and design of variable domain sequences before in vivo testing. By pre-optimizing these critical parameters in silico and in vitro, the invention reduces the number of iterative in vivo experiments needed, thereby improving in vivo potency while minimizing the time and resources required for systematic evaluation.
3Manufacturing precision
If bispecific molecules are designed with specific amino acid sequences and configurations, then binding affinity to ROR1 and CD3 is enhanced, but the difficulty of manufacturing and testing increases
Solution Approach 1:
The patent systematically optimizes amino acid sequences in the variable domains and spatial configurations of paratopes to achieve high binding affinity for both ROR1 and CD3. These parameter optimizations are implemented through structured molecular design approaches that balance manufacturing feasibility, allowing production of defined bispecific constructs with predictable and reproducible binding characteristics.
Data Source
AI summary
This invention relates to bispecific binding molecules that bind to ROR1 and CD3, and methods of using them to treat diseases and conditions such as cancer.